LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Elenco Azioni・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

22.44 -2.69

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

22.44

Massimo

23.29

Metriche Chiave
By Trading Economics
Entrata	675K 53M
Vendite	1.8M 148M
P/E Media del settore	13.269 80.03
Margine di Profitto	35.57
Dipendenti	181
EBITDA	1.7M 80M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+46.8% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	165M 2.8B
Apertura precedente	25.13
Chiusura precedente	22.44

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

N/A / 24.28 Supporto e resistenza

Catalyst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 dic 2025, 22:13 UTC

Utili

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 dic 2025, 21:40 UTC

Utili

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 dic 2025, 18:51 UTC

Acquisizioni, Fusioni, Takeovers

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 dic 2025, 16:57 UTC

I principali Market Mover

Clear Secure Rises on Medicare Identity Verification Contract

9 dic 2025, 23:46 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 dic 2025, 23:46 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings Stake in Lenovo Now at 32.34%

9 dic 2025, 23:45 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 dic 2025, 23:44 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 dic 2025, 23:43 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 dic 2025, 23:43 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 dic 2025, 23:35 UTC

Discorsi di Mercato

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 dic 2025, 22:42 UTC

Utili

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 dic 2025, 21:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

9 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 dic 2025, 21:48 UTC

Discorsi di Mercato

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 dic 2025, 20:28 UTC

Discorsi di Mercato

Oil Futures Decline for Second Straight Session -- Market Talk

9 dic 2025, 20:27 UTC

Acquisizioni, Fusioni, Takeovers

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 dic 2025, 20:27 UTC

Acquisizioni, Fusioni, Takeovers

Teck Reports Voting Results From Special Meeting of Hldrs

9 dic 2025, 20:26 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 dic 2025, 20:21 UTC

Discorsi di Mercato

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 dic 2025, 19:52 UTC

Utili

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 dic 2025, 19:17 UTC

Utili

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 dic 2025, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 dic 2025, 17:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

9 dic 2025, 17:11 UTC

Utili

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Catalyst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

46.8% in crescita

Previsioni per 12 mesi

Media 34 USD 46.8%

Alto 35 USD

Basso 33 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 24.28Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.